Germany market view

Germany biotech and pharma directory

German biotech, pharma, diagnostics, CDMO, and manufacturing companies — 55+ hand-reviewed profiles. The strongest clusters are Heidelberg (BioRN, DKFZ, BioNTech), Berlin (Bayer, Berlin-Chemie, MDC), Mainz (BioNTech, Boehringer), Munich, and Hamburg. Most carry GMP or ISO 13485 certification, several are FDA-inspected for US-bound supply.

Evidence

Visible records55

German records55

Cities covered28

Regulated sites31

Avg sources / record0.0

In-depth analysis

Read the related market brief

Deep-dive editorial map of this region’s operators, capabilities, partnerships, and regulatory landscape.

German Biotech Landscape 2026Map of Heidelberg, Berlin, Mainz, Hamburg, Tübingen operators, capabilities, BioRN cluster, BioNTech, CureVac, Bayer, Merck KGaA.Swiss vs German Biotech Manufacturing 2026Side-by-side comparison of manufacturing capacity, GMP/FDA inspection records, CDMO partners.European CDMO Capacity 2026European biologics + small-molecule CDMO capacity map including Boehringer Ingelheim, IDT Biologika, Vetter, Wacker.

Featured records

Start with the strongest profiles

These are the best-covered records in this region and the right place to start a serious review.

altona Diagnostics GmbH BioSpring GmbH Cardior Pharmaceuticals GmbH CeGaT GmbH

Full list

Regional records

55 regional records currently match the active filter.

Hamburg ISO 13485-certified molecular diagnostics manufacturer building CE-IVD real-time PCR assays for infectious disease, with global distribution through subsidiaries and a historical FDA EUA track record for its RealStar Ebolavirus assay.

Lead: Soenke FriedrichsenManaging Director (joint with Hans Kuhn)
Scale: Commercial CE-IVD diagnostic manufacturing

Frankfurt-based oligonucleotide CDMO producing antisense oligonucleotides, siRNA, guide RNA and mRNA at research-to-commercial scale, with a documented cGMP track record since 2007 and FDA-inspected commercial supply since 2020.

Lead: Sylvia WojczewskiCo-Founder and Chief Executive Officer
Scale: Research through multi-kilogram commercial oligonucleotide API

Hannover RNA-targeting cardiovascular therapeutics company developing CDR132L, a miR-132 antisense inhibitor in Phase 2 for heart failure, now operating as a wholly-owned Novo Nordisk subsidiary after the approximately one billion euro 2024 acquisition.

Lead: Claudia UlbrichChief Executive Officer and Co-Founder
Scale: Clinical-stage drug development under Novo Nordisk umbrella

Tuebingen clinical NGS genomic diagnostics operator running diagnostic panels, whole-exome and whole-genome sequencing, and research sequencing services under DIN EN ISO 15189 and DIN EN ISO 17025 accreditations, with CAP and CLIA recognition.

Lead: Saskia BiskupManaging Director and Co-Founder
Scale: Clinical and research genomic service delivery

Hamburg AI and multi-omics precision-oncology therapeutics company, built on the IndivuType cancer database and a global clinical-site network, after the 2023 services and biobank arm divestment to Crown Bioscience.

Lead: Hartmut JuhlFounder and Chief Executive Officer
Scale: AI-driven target discovery and early compound development

Hamburg clinical-stage biotech developing antigen-specific nanoparticle therapeutics to induce immune tolerance, with TPM502 for celiac disease completing Phase 2a in 2025.

Lead: Hugo FryChief Executive Officer
Scale: Clinical-stage therapeutics development

Munich-area antibody-drug conjugate biotech with the proprietary P5 conjugation platform and tubutecan payload class, advancing the TUB-040 lead candidate in solid tumors after a 2025 Series C of approximately 308 million euros.

Lead: Dominik SchumacherChief Executive Officer and Managing Director
Scale: Research to clinical-stage ADC development

Heidelberg antibody and antibody-drug conjugate platform company offering target-to-ADC discovery partnerships to oncology programs, with a proprietary high-throughput antibody screening engine.

Lead: Christoph AntzManaging Director and Chief Executive Officer
Scale: Research-stage discovery and partnership delivery

Mainz diagnostics company focused on autoimmune and infectious-disease testing, with broad immunology assay operations from a German IVD platform.

Lead: Gregoire AllazChief Executive Officer
Scale: Diagnostics platform

Mainz diagnostics company developing molecular screening tests for colorectal and pancreatic cancer from a German diagnostics base.

Lead: Guido BaechlerChief Executive Officer
Scale: Diagnostics platform

Heidelberg molecular diagnostics company developing miRNA-based liquid-biopsy assays for neurological disease and oncology applications.

Lead: Tillman WeissChief Executive Officer
Scale: Diagnostics platform

Heidelberg cell-therapy company developing tolerogenic dendritic-cell approaches for autoimmune disease and transplant-related applications.

Lead: Matthias SchaierChief Executive Officer
Scale: Clinical-stage cell-therapy platform

Heidelberg biomanufacturing site within AGC Biologics, providing microbial, pDNA, and mRNA process development and GMP manufacturing services from Germany.

Lead: Patrik JonssonChief Executive Officer
Scale: Commercial and clinical manufacturing platform

Berlin peptide-technology company producing research, assay, and clinical-grade peptide products for immunology, oncology, and biomarker workflows.

Lead: Aurelien ClaeyssenManaging Director
Scale: Global peptide products platform

Berlin radiopharmaceutical company developing peptide-targeted cancer therapeutics and companion diagnostics from a German translational-oncology base.

Lead: Ulrich HaagmannChief Executive Officer
Scale: Development-stage radiopharma platform

Berlin organ-on-chip company developing multi-organ microphysiological systems for drug development, toxicology, and advanced human tissue models.

Lead: Uwe MarxChief Executive Officer
Scale: Research-platform operations

Berlin T-cell therapy company building TCR-engineered cell therapies for solid tumors from a German oncology platform.

Lead: Gabriele EisnerChief Executive Officer
Scale: Clinical-stage cell-therapy platform

Berlin CDMO and biologics technology company providing cell-line development, process development, and GMP manufacturing services for complex biopharmaceuticals.

Lead: Volker SandigChief Executive Officer and Chief Scientific Officer
Scale: Commercial and clinical biopharma platform

Heidelberg cancer-research flagship integrating oncologic discovery, prevention, translational programmes, and national research infrastructure.

Lead: Prof. Dr. Michael BaumannChairman and Scientific Director
Scale: Large national oncology-research centre

Rhine-Neckar life-science cluster platform connecting biotech companies, research institutions, investors, and translational programmes across Heidelberg.

Lead: Dr. Julia SchaftManaging Director
Scale: Rhine-Neckar cluster coordination hub

Berlin-Buch science and biotech campus integrating research institutes, translational platforms, spinouts, and grow-out infrastructure for biomedical companies.

Lead: Dr. Christina Quensel / Dr. Ulrich SchellerManaging Directors
Scale: Berlin-Buch biotech campus operations

Berlin radiopharma and isotope-products anchor spanning medical isotopes, radiation components, and nuclear-medicine supply.

Lead: Dr. Harald HasselmannChief Executive Officer
Scale: International isotope and radiopharma platform

Heidelberg European molecular-biology site linking structural biology, genomics, data, and international training infrastructure into the wider cluster.

Lead: Jan KorbelInterim Head of Site, EMBL Heidelberg
Scale: European molecular-biology flagship site

Berlin biologics-development and bioanalytical platform supporting cell-line development, CMC, and analytical packages for biopharma programmes.

Lead: Philippe UlsemerCo-Founder and Chief Executive Officer
Scale: Integrated biologics-development platform

Market scale

Germany is the directory’s deepest large-scale market.

The German layer covers large-scale manufacturing, diagnostics, therapeutics, research infrastructure, and a broad range of quality-governed sites.

Practical value

Use this page to benchmark scale, maturity, and specialization.

German records give essential context for comparing Baltic and Polish companies against a broader European operating market.

Browse by

Cities, categories, and compliance

Jump into a specific city, category, or compliance-standard page for a more focused view.

Cities

Heidelberg (10)Berlin (9)Hamburg (5)Mainz (3)

Compliance standards

GMP-documented in Germany (19)GLP-documented in Germany (9)ISO-13485-documented in Germany (9)FDA-Inspected-documented in Germany (3)

Frequently asked questions

Questions about germany biotech and pharma directory

How many biotech companies are in Germany?

The Memel Biotech directory lists 55+ verified German biotech, pharma, diagnostics, and manufacturing companies. Germany is the directory's largest single-country layer.

What are the main biotech cities in Germany?

The strongest biotech clusters are Heidelberg (BioRN, DKFZ, BioNTech), Berlin (Bayer, MDC, Berlin-Chemie), Mainz (BioNTech), Munich (MorphoSys, Roche Diagnostics), and Hamburg (Evotec, Olympus Diagnostics). Each city has a distinct specialization mix.

What compliance standards do German biotech companies hold?

German companies in the directory commonly hold GMP, ISO 13485, and GLP certifications. Large manufacturing sites also carry FDA inspection markers for US-bound supply.

What is Germany known for in biotech?

Germany has Europe's deepest industrial biotech footprint — mRNA vaccines (BioNTech, CureVac), large-scale CDMO (Boehringer Ingelheim, Vetter, IDT Biologika), diagnostics leaders (Roche, Qiagen), and therapeutic platforms (Bayer, Merck KGaA).

Can I compare two German biotech companies side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

Next step

Compare Germany with Switzerland, Poland, and Lithuania.

Move from Germany into Switzerland for premium benchmarks, Poland for market scale, or Lithuania for Baltic comparison.

Open Switzerland Open Lithuania Open Poland